Efficacy and safety of Osimertinib and other third-generation EGFR TKIs in advanced NSCLC: a systematic review and meta-analysis.

Discov Oncol · 2026 · PMC12873059 · PMID 41501563

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significanceP = 0.08so close (0.05 < p ≤ 0.1)

Although an increased incidence of rash and QT interval prolongation was observed in some studies, the meta-analysis did not reach statistical significance (rash: P = 0.08; QT prolongation: P = 0.08), and further validation is needed.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.